In This Article:
HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here.
Dr. Retter will focus on Nu.Q® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.
Mr. Forterre will provide an update on Volition's progress to commercialization through both licensing and direct and indirect sales.
A live question and answer session will follow the formal presentations.
About Dr. Andrew Retter
Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care, ECMO & Thrombois and also the Clinical Lead for Critical Care at one of the UK's largest hospitals in London, where he has worked as a Consultant since 2014. He is also the Chief Medical Officer at Volition, a medical technology company that specializes in developing innovative diagnostic tools for cancer, sepsis and in particular immunothrombosis. Dr Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals.
About Gael Forterre
Gael Forterre is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q® platform. Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Pathify. He is currently the non-executive chairman of Vahau.
Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.